Next Article in Journal
Pathophysiological Implication of Pattern Recognition Receptors in Fetal Membranes Rupture: RAGE and NLRP Inflammasome
Next Article in Special Issue
Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design
Previous Article in Journal
Spns2 Transporter Contributes to the Accumulation of S1P in Cystic Fibrosis Human Bronchial Epithelial Cells
Previous Article in Special Issue
Battle Royale: Innate Recognition of Poxviruses and Viral Immune Evasion
Review

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus

by 1,*,†, 1,*,† and 2,*,†
1
Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain
2
Unidad de Presentación y Regulación Inmunes, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Spain
*
Authors to whom correspondence should be addressed.
These authors contribute equally.
Academic Editor: Michael H. Lehmann
Biomedicines 2021, 9(9), 1122; https://doi.org/10.3390/biomedicines9091122
Received: 13 April 2021 / Revised: 19 August 2021 / Accepted: 20 August 2021 / Published: 31 August 2021
(This article belongs to the Special Issue Poxviruses: From Pathophysiology to Novel Therapeutic Approaches)
There is a need to develop a highly effective vaccine against the emerging chikungunya virus (CHIKV), a mosquito-borne Alphavirus that causes severe disease in humans consisting of acute febrile illness, followed by chronic debilitating polyarthralgia and polyarthritis. In this review, we provide a brief history of the development of the first poxvirus vaccines that led to smallpox eradication and its implications for further vaccine development. As an example, we summarize the development of vaccine candidates based on the modified vaccinia virus Ankara (MVA) vector expressing different CHIKV structural proteins, paying special attention to MVA-CHIKV expressing all of the CHIKV structural proteins: C, E3, E2, 6K and E1. We review the characterization of innate and adaptive immune responses induced in mice and nonhuman primates by the MVA-CHIKV vaccine candidate and examine its efficacy in animal models, with promising preclinical findings needed prior to the approval of human clinical trials. View Full-Text
Keywords: poxvirus; vaccinia virus; MVA; vaccine; chikungunya virus poxvirus; vaccinia virus; MVA; vaccine; chikungunya virus
Show Figures

Figure 1

MDPI and ACS Style

García-Arriaza, J.; Esteban, M.; López, D. Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus. Biomedicines 2021, 9, 1122. https://doi.org/10.3390/biomedicines9091122

AMA Style

García-Arriaza J, Esteban M, López D. Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus. Biomedicines. 2021; 9(9):1122. https://doi.org/10.3390/biomedicines9091122

Chicago/Turabian Style

García-Arriaza, Juan, Mariano Esteban, and Daniel López. 2021. "Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus" Biomedicines 9, no. 9: 1122. https://doi.org/10.3390/biomedicines9091122

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop